TP53INP1 dysregulation has been associated with enhanced tumor survival and resistance to therapy, suggesting that miR-155 suppression of TP53INP1 may provide an additional advantage to VEGF-driven tumorigenesis [89]. This evidence concerns the gene TP53INP1 and neoplasm.